Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.

[1]  S. Ritland,et al.  Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Anemia Due to Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS): Preliminary Results from Phase 2 Studies , 2016 .

[2]  G. Mufti,et al.  Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[4]  J. Barnard,et al.  Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs) , 2015 .

[5]  P. Campbell,et al.  SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. , 2015, Blood.

[6]  L. Hofbauer,et al.  Myelodysplasia is in the niche: novel concepts and emerging therapies , 2014, Leukemia.

[7]  I. Boyd,et al.  A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers , 2014, American journal of hematology.

[8]  A. Grinberg,et al.  Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis , 2014, Nature Medicine.

[9]  C Haferlach,et al.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.

[10]  M. Cazzola,et al.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. , 2013, Blood.

[11]  P. Fenaux,et al.  How we treat lower-risk myelodysplastic syndromes. , 2013, Blood.

[12]  A. Jankowska,et al.  SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. , 2012, Blood.

[13]  A. Trumpp,et al.  Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. , 2012, Blood.

[14]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[15]  L. Hofbauer,et al.  The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. , 2012, Leukemia research.

[16]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[17]  M. Bitzer,et al.  Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. , 2011, Cancer research.

[18]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[19]  M. Bitzer,et al.  Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. , 2008, Blood.

[20]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[21]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.